Skip to content
Study details
Enrolling now

Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS

Philip Morris Products S.A.
NCT IDNCT07108166ClinicalTrials.gov data as of Apr 2026
Target enrollment

290

Study length

about 1.7 years

Ages

40+

Locations

44 sites in FL, GA, TX

What this study is about

Researchers are testing whether switching from cigarette smoking to a treatment called THS improves symptoms like cough frequency and shortness of breath, as well as lung function, in people with COPD and chronic bronchitis. The trial will last for 607 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Cigarette
  • 2.THS

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Changes in lung function (from Baseline in FEV1 post-bronchodilator), Changes in the Cough Quality of Life Questionnaire (CQLQ) on chronic cough

Body systems

Respiratory